ReviewExpert review of neurotherapeutics2016
Precision medicine of aneurysmal subarachnoid hemorrhage, vasospasm and delayed cerebral ischemia.
Review in Expert review of neurotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of nicardipine prolonged-release implants in patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of randomized controlled trials.Neurosurgical review · 2025Pooled it
- Laboratory biomarkers of delayed cerebral ischemia after subarachnoid hemorrhage: a systematic review.Neurosurgical review · 2020Pooled it
- Cerebral Vasospasm After Traumatic Subarachnoid Hemorrhage: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Subarachnoid hemorrhage: epidemiology, risk factors, pathogenesis, and clinical therapies.Molecular biomedicine · 2026Review
- Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics.The pharmacogenomics journal · 2024Article
- The impact of collateral status on cerebral vasospasm and delayed cerebral ischemia in subarachnoid hemorrhage.Journal of cerebrovascular and endovascular neurosurgery · 2023Article
- Circulating Metabolites as Potential Biomarkers for Neurological Disorders-Metabolites in Neurological Disorders.Metabolites · 2020Article
- mRNA Expression Profiles from Whole Blood Associated with Vasospasm in Patients with Subarachnoid Hemorrhage.Neurocritical care · 2020Article
- Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 as a biomarker of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.Brain and behavior · 2020Article
- Time Course of Metabolomic Alterations in Cerebrospinal Fluid After Aneurysmal Subarachnoid Hemorrhage.Frontiers in neurology · 2020Article
- Endothelial Cell Dysfunction and Injury in Subarachnoid Hemorrhage.Molecular neurobiology · 2019Review
- Mesenchymal stem cells for hemorrhagic stroke: status of preclinical and clinical research.NPJ Regenerative medicine · 2019Review
- Utility of cerebrospinal fluid lactate in aneurysmal subarachnoid hemorrhage.Surgical neurology international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionPrecision medicine provides individualized treatment of diseases through leveraging patient-to-patient variation. Aneurysmal subarachnoid hemorrhage carries tremendous morbidity and mortality with cerebral vasospasm and delayed cerebral ischemia proving devastating and unpredictable. Lack of treatment measures for these conditions could be improved through precision medicine. Areas covered: Discussed are the pathophysiology of CV and DCI, treatment guidelines, and evidence for precision medicine used for prediction and prevention of poor outcomes following aSAH. A PubMed search was performed using keywords cerebral vasospasm or delayed cerebral ischemia and either biomarkers, precision medicine, metabolomics, proteomics, or genomics. Over 200 peer-reviewed articles were evaluated. The studies presented cover biomarkers identified as predictive markers or therapeutic targets following aSAH. Expert commentary: The biomarkers reviewed here correlate with CV, DCI, and neurologic outcomes after aSAH. Though practical use in clinical management of aSAH is not well established, using these biomarkers as predictive tools or therapeutic targets demonstrates the potential of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.